Trung Huynh
Stock Analyst at UBS
(4.49)
# 284
Out of 4,918 analysts
47
Total ratings
61.29%
Success rate
20.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Neutral | $315 → $326 | $300.16 | +8.61% | 5 | Jul 21, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $560 → $584 | $566.80 | +3.03% | 4 | Jul 11, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $38 → $33 | $2.95 | +1,018.64% | 2 | May 13, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $21.93 | +73.28% | 2 | May 9, 2025 | |
| INSM Insmed | Maintains: Buy | $110 → $109 | $109.99 | -0.90% | 5 | May 9, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,100 → $1,050 | $767.27 | +36.85% | 8 | May 2, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $23.65 | +5.73% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $45.30 | +19.21% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $1.51 | +363.24% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $3.43 | +279.21% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $170.02 | +2.93% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $79.85 | +57.80% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $197.10 | -13.75% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $10.72 | - | 1 | Mar 23, 2021 |
Amgen
Jul 21, 2025
Maintains: Neutral
Price Target: $315 → $326
Current: $300.16
Upside: +8.61%
Regeneron Pharmaceuticals
Jul 11, 2025
Maintains: Neutral
Price Target: $560 → $584
Current: $566.80
Upside: +3.03%
Jasper Therapeutics
May 13, 2025
Maintains: Buy
Price Target: $38 → $33
Current: $2.95
Upside: +1,018.64%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $21.93
Upside: +73.28%
Insmed
May 9, 2025
Maintains: Buy
Price Target: $110 → $109
Current: $109.99
Upside: -0.90%
Eli Lilly and Company
May 2, 2025
Maintains: Buy
Price Target: $1,100 → $1,050
Current: $767.27
Upside: +36.85%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $23.65
Upside: +5.73%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $45.30
Upside: +19.21%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.51
Upside: +363.24%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $3.43
Upside: +279.21%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $170.02
Upside: +2.93%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $79.85
Upside: +57.80%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $197.10
Upside: -13.75%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $10.72
Upside: -